IMPORTANCE Management of antithrombotic medications presents a challenge for many clinicians and patients before procedures. Anticoagulation clinic involvement may improve preprocedure coordination, satisfaction on the part of patients and clinicians, last-minute procedure cancellations, and patient safety.
Introduction
Managing chronic antithrombotic (anticoagulant and/or nonaspirin antiplatelet) medications before an elective procedure is a common clinical challenge for patients with atrial fibrillation, venous thromboembolism, and coronary artery disease. 1 Frequently these antithrombotic medications are not managed in accordance with clinical trial evidence or guideline recommendations, placing patients at risk for bleeding or thrombotic complications. 2 In the context of gastrointestinal endoscopy, a recent survey found that most primary care clinicians (including physicians, nurse practitioners, and physician assistants) and gastroenterologists did not believe that they should be responsible for preendoscopy antithrombotic medication management and often recommended management that was not congruent with the most recent randomized clinical trial evidence. 3 In addition, more than 80% of primary care clinicians and gastroenterologists indicated that their institution could do more to help manage preendoscopy antithrombotic medications. 4 For their part, patients also commonly express confusion and dissatisfaction with the coordination of their medications before elective procedures. 5 Before procedures, antithrombotic medications may be managed by 1 of 3 health care professionals: (1) the original prescriber of the drug (eg, cardiologist); (2) the proceduralist (eg, gastroenterologist); or (3) the referring clinician (eg, primary care clinician). Poorly coordinated preprocedure antithrombotic medication management can lead to inefficient and unsafe care, poor patient satisfaction, and potential delays in care delivery. 5 Although particularly robust anticoagulation clinics may assist with preprocedural anticoagulant management, fewer assist with managing antiplatelet medication before procedures, despite frequent concurrent use of anticoagulant and antiplatelet medications. 6, 7 Anticoagulation clinics that provide preprocedure anticoagulant management often do so selectively and without an established referral process.
Because gastrointestinal endoscopy is one of the most commonly performed elective procedures for patients with long-term use of antithrombotic medications, we formed a multidisciplinary quality improvement team at our institution to redesign the process for managing preendoscopy antithrombotic medications for outpatients. This process resulted in the development of a best practice alert (BPA) within the electronic medical record (EMR) that recommended referral to the anticoagulation clinic for any outpatients currently using long-term antithrombotic medication therapy (other than aspirin) when an elective gastrointestinal endoscopy was ordered. Our objective was to evaluate acceptability, adoption, and effectiveness of preendoscopic antithrombotic management and patient and clinician satisfaction.
Implementation Process
In November 2017, a new BPA was piloted within 2 clinics (1 gastroenterology and 1 primary care) and slowly expanded to additional clinics during the next 5 months. By April 2018, the BPA was active for the entire health system. The BPA is triggered when an outpatient, elective gastrointestinal endoscopic procedure is ordered for a patient who is found to be using an antithrombotic medication (anticoagulant or P2Y12 inhibitor antiplatelet). The BPA notifies the ordering clinician that the patient appears to be using an antithrombotic medication and recommends referral to the anticoagulation clinic for further management. The ordering clinician can accept the referral or decline and opt to manage the antithrombotic medication(s) on his or her own. Before implementation, opinion leaders within each of the specialties (gastroenterology, family medicine, general medicine, and gynecology) most likely to order gastrointestinal endoscopic procedures were identified. They communicated with their colleagues about the BPA and referral process, acting in a physician champion role and as a liaison between their colleagues and the multidisciplinary team. Educational sessions led by one of us (J.E.K.) were held with the gastroenterology faculty during 2 faculty meetings. Communications via email were sent to all clinicians who frequently order gastrointestinal endoscopic procedures. There was also a notice about the BPA and referral process in the weekly information technology newsletter sent to all faculty and staff.
Data Collection and Implementation Outcomes Assessment
Four sets of data to measure the outcomes of implementing this BPA were collected. These outcomes cover the range of implementation, service, and client outcomes described by Proctor et al. 8 Specifically, we assessed adoption of the BPA from EMR-based data and patient reports of which clinicians gave preprocedural instructions. We assessed acceptability and fidelity of the BPA and anticoagulation clinic referral process through clinician surveys. We assessed the effectiveness of the quality improvement intervention by measuring the frequency of a cancelled procedure. Finally, we assessed patient and clinician satisfaction as well as patient-centeredness through surveys.
Patient Surveys
We collected patient-reported data from a structured telephone survey. We identified consecutive patients who had recently completed an outpatient, elective gastrointestinal endoscopic procedure while prescribed an antithrombotic medication. Within 2 business days of their procedure, after obtaining verbal informed consent, patients answered questions that were entered into a web-based survey database (Qualtrics) by a research team member (E. Sippola). These surveys were conducted from May 25 through December 19, 2017, before implementation of the BPA and then from June 19 through November 30, 2018, after implementation. The survey assessed patients' experience and satisfaction with preendoscopic management and coordination of their antithrombotic medication.
The complete survey instrument can be seen in eAppendix 1 in the Supplement.
Clinician Surveys
We assessed changes in the clinician-reported experience using online surveys (Qualtrics) before and after implementation. The first wave of surveys was sent to all attending cardiologists, gastroenterologists, and primary care clinicians at our center in the summer of 2015 (before implementation). This current analysis only includes primary care clinicians and gastroenterologists who responded to that survey, because cardiologists rarely order endoscopic procedures. The second wave of surveys was sent to all gastroenterologists and primary care clinicians who had managed 2 or more patients when the BPA was triggered from April 1 through July 31, 2018. This survey was administered from October 11 through December 19, 2018 (after implementation). 
Process Measures
We used 2 complementary approaches to assess for canceled or altered procedures. First, we sampled patients presenting to the endoscopy unit for elective gastrointestinal endoscopic procedures in 3 waves. Endoscopy unit nurses completed a form if the patient was using an antithrombotic medication. The form assessed the specific antithrombotic medication and planned procedure, if the procedure had to be altered owing to mismanagement of the antithrombotic medication (eg, will perform colonoscopy but not perform a polypectomy), or if the procedure was canceled owing to mismanagement of the antithrombotic medication (herein referred to as same-day cancelation). These data were collected at all outpatient endoscopy units from June 1 through August 17, 2017, before implementation; from June 18 through July 2, 2018, shortly after full systemwide implementation; and from November 5 through 16, 2018, further after implementation.
Analysis was performed by comparing the preimplementation phase with the combination of both postimplementation phases.
Second, we used the EMR to identify all endoscopic procedures scheduled from January 1, 2016, through April 30, 2019, that were canceled within 24 hours before their scheduled date (herein referred to as cancelation within 24 hours). We compared monthly cancelation rates before (January 2016 through October 2017) and after (May 2018 through April 2019) implementing the BPA (eFigure 6 in the Supplement).
To assess for use of the BPA implementation quality improvement intervention, we collected data for all instances of the BPA occurring from November 1, 2017 , through December 19, 2018 . Each 
Quality Goals
The team set goals before implementation. These included more than 80% patient and clinician satisfaction with preprocedural antithrombotic medication management, less than 5% of endoscopy cases requiring alteration or cancelation due to medication mismanagement, and broad use (>50%) of the anticoagulation clinic referral as recommended by the BPA.
Statistical Analysis
Data were analyzed in September 2019. We report descriptive statistics using χ 2 
Results

Preimplementation Phase
A total of 2082 patients (mean [SD] age, 64.1 [11.9] years) and 144 clinicians were included in the analysis. Several key findings emerged from the preimplementation process. First, gastrointestinal endoscopic procedures were ordered by multiple specialties (eg, gastroenterologist, primary care clinician) who were not all familiar with (1) the safety of stopping therapy with various antithrombotics (P2Y12 inhibitor and oral anticoagulant) in a specific clinical context or (2) the bleeding risk associated with specific endoscopic procedures (primarily among nongastroenterologists). Second, the pharmacists within the anticoagulation clinic provided only ad hoc assistance when specifically requested regarding preprocedure anticoagulant management (including warfarin sodium and the direct oral anticoagulants) but not antiplatelet medications.
Third, endoscopy schedulers were a focal point in the coordination of care for patients using antithrombotic medications. Specifically, they were the group most likely to identify patients using an antithrombotic medication, because all patients (from internal and external referring clinicians) scheduling a procedure had to talk with a scheduler. In addition, schedulers had been trained to screen for antithrombotic medication use and, when needed, to direct patients to their referring clinicians for further instructions regarding preprocedure antithrombotic medication management.
No formal process was in place to ensure that a plan for antithrombotic medication management was reached or that it was communicated to the patient and/or their family. The team thus concluded that the central challenges to safe, effective, and efficient preprocedure medication management were consistently identifying the clinician responsible for preprocedure medication management and standardizing that management decision in accordance with the best evidence.
Postimplementation Phase Adoption and BPA Use
During the study period, the BPA resulted in a referral to the anticoagulation clinic in 1389 of 2082 cases (66.7%) with endoscopy orders among patients using antithrombotic medications (study flowchart in eFigure 1 in the Supplement). Overall use of the BPA increased during the pilot phase as it was sequentially rolled out to new clinics until it reached a plateau by May 2018, when it was being used across the entire health system (Figure 1) . As shown in Table 1 , referral was less common during the pilot phase compared with the implementation phase (308 of 495 [62.2%] vs 1081 of 1587 
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Effectiveness: Endoscopy Unit Experience
Data from 102 patients presenting to endoscopy were collected and analyzed in the same-day 
Patient Experience Survey
A total of 122 of 130 patients (93.8%) completed the structured survey (74 before implementation and 48 after implementation) to measure adoption, patient centeredness, and satisfaction ( (Figure 2A) . There was also a shift in preprocedure instructions being given by telephone (24 of 36 [66.7%]) compared with in person (4 of 36 [11.1%]) or by mailed letter (7 of 36 [19.4%]), but this difference was not statistically significant (P = .27) ( Figure 2B ).
In the preimplementation and postimplementation phases, patient satisfaction with communication about and coordination of preendoscopy antithrombotic medications was high (61 of 72 [84.7%] for preimplementation vs 41 of 43 [95.3%] for postimplementation; P = .08). Similarly, preimplementation vs postimplementation for each, P = .01). As shown in Figure 3 , opinions about institutional care processes for preprocedure antithrombotic management improved after implementation.
Among the survey respondents who had been exposed to the BPA (n = 48), their recollection of the BPA and satisfaction were high (eFigure 3 in the Supplement). After implementation of the BPA, responding clinicians were more likely to agree that the anticoagulation clinic provided assistance with determining the need for periprocedural bridging anticoagulation (18 of 
Discussion
In response to patient-and clinician-reported difficulty managing preprocedure antithrombotic medications leading to frequent same-day endoscopy cancelation, we implemented a BPA that recommended referral to the anticoagulation clinic for medication management assistance. That effort was successful across a broad range of implementation outcomes, including acceptability, adoption, fidelity, effectiveness, patient centeredness, and satisfaction. 8
Most clinicians acted on this BPA to refer patients to the anticoagulation clinic for preprocedure medication management. After implementation of this BPA, clinician satisfaction improved. In addition, the overall number of canceled or altered procedures was reduced in the same-day endoscopy unit sample with a significant reduction found in the EMR-based analysis of cancelations within 24 hours. While achieving these improvements, patient satisfaction remained very high, and
there was growing support for and awareness of the anticoagulation clinic's role in managing preprocedure antithrombotic medications among primary care clinicians and gastroenterologists.
Antithrombotics remain one of the highest-risk medications for adverse drug events. 9 The periprocedural period is particularly high risk, given the number of short-term medication changes and the risk of thromboembolic and bleeding events around the time of a procedure. 10 At the same time, the evidence guiding periprocedural management decisions has been changing rapidly during the past 5 years. This evidence includes new recommendations to be less aggressive with heparin bridging for warfarin-treated patients, 4 new direct oral anticoagulants with unique pharmacological properties that differ greatly from those of warfarin, and no clear source of national recommendations for P2Y12 antiplatelet management for noncardiac surgery. 1, 11 The revised preendoscopy workflow in this project leverages the expertise of an existing anticoagulation clinic, helping to expand its scope of work and reach. With the increasing diversity of antithrombotic medications being used clinically, anticoagulation clinics have an opportunity to serve many roles to promote safe medication use, including in the periprocedural period. 6 However, justifying the use of these important staff members requires careful implementation evaluation.
Consistent with the framework first presented by Proctor and colleagues, 8 we believe we have demonstrated successful implementation across the domains of implementation outcomes (acceptability, adoption, and fidelity), service outcomes (effectiveness and patient centeredness), and client outcomes (satisfaction). 8 Important to health care administrators, avoiding canceled procedures can greatly improve revenue capture for these procedures. With the use of ongoing analyses, we hope to assess the association of the BPA and anticoagulation referral process with guideline-recommended management.
Although this project was specific to gastrointestinal endoscopy, it has the potential to be generalizable to many other elective surgical procedures. As a central repository of anticoagulation expertise, the anticoagulation clinic can support preprocedure management care coordination, decision-making, and communication for any number of different procedures (eg, cardiac procedures or elective orthopedic or general surgical procedures). In addition, the BPA leverages information routinely collected in the EMR (eg, current medications) to identify which patients would be appropriate for a referral to the anticoagulation clinic. We believe that by designing this BPA as part of the current clinician workflow (alert occurs at the time the endoscopy order is placed, not hours or days later) and using an opt-out design that allows single-click ordering, overall clinician satisfaction is optimized and use of BPA is encouraged. This outcome is particularly important given that more than one-quarter of variation in referral to the anticoagulation clinic is explained by individual clinician differences. Creating standard workflows that ensure high-quality care for all patients is a laudable goal, and further work is needed to explore how to better operationalize BPAs and other clinical prompts.
Although overall rates of inappropriate medication management or same-day procedure cancelation were quite low, these rates improved after implementing the BPA and anticoagulation clinic referral process. When combined with the increases in patient and clinician satisfaction, the implementation was deemed to be a success and may serve as a model for other procedures or health systems looking to similarly improve their periprocedural antithrombotic medication management.
Strengths and Limitations
This study has a number of important strengths, including complementary data collection from multiple stakeholder groups and the use of validated survey instruments for patient-and clinicianreported outcomes. However, a few important limitations must be acknowledged. First, this implementation effort was conducted at a single academic health center, and the outcomes reported may not be realized at different health centers with a different patient, clinician, and/or resource mix.
Second, although data collection was completed concurrently with implementation, causation cannot be inferred from these findings. Third, some data collected were sampled (eg, endoscopic procedure alteration or cancelation) using on-site endoscopy unit staff. Therefore, those estimates may include measurement error and/or bias in the estimates. Other data were captured from the EMR. As with most quality improvement studies, limited data collection may introduce possible unmeasured confounding. Fourth, the clinician survey response rate was low and may not represent the attitudes of all clinicians. Fifth, although we have demonstrated changes in attitudes and procedural outcomes, we were unable to assess for any change in clinical outcomes (eg, bleeding or
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Conclusions
We redesigned the management of preprocedure antithrombotic medications before elective gastrointestinal endoscopic procedures by using an EMR BPA to encourage referral to the anticoagulation clinic. Successful implementation of this new process was associated with improved patient and clinician satisfaction, a low rate of medication mismanagement, and a substantial reduction in canceled elective endoscopic procedures.
